Clinical trials: Multivariate Risk Assessment for ISUP ≥2 Prostate Cancer
Multivariate Risk Assessment for ISUP ≥2 Prostate Cancer
RPCRC Validation Study
Prostate multiparametric MRI (mpMRI) can detect ISUP ≥2 prostate cancer with high sensitivity. Adding biopsies targeting suspicious lesions seen on mpMRI to the classical 'systematic biopsies' (that sample the gland in a blinded…
- Trial name
- PCaRisk (NCT04484103)
- Testing
- Assessment of the diagnostic performance of the PI-RADS score (as a stand-alone) and of the RPCRC for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in 251 patients.
- Where
- France
- Volunteers
- 275 people
- Sponsor
- Hospices Civils de Lyon